title: Prognostic significance of immunohistochemically detected lymph node micrometastases in pT0N0 esophageal squamous cell carcinoma.
abstract: BACKGROUND
  Pathological complete response (pCR) after chemoradiotherapy (CRT) is the best predictor of survival in patients with squamous cell carcinoma (SCC) of the esophagus. Although no adjuvant treatment is recommended for individuals who achieve pCR, approximately 30% of these patients develop a recurrence. We applied an immunohistochemistry (IHC) stain on resected lymph nodes to evaluate the incidence of lymph node micrometastases (LNMs) and its prognostic significance.
  
  
  METHODS
  Between 1995 and 2004, paraffin-embedded specimens for evaluating the presence of LNM were available for 52 pCR patients. We performed IHC staining with the cytokeratin antibody AE1/AE3 on resected lymph nodes and correlated the pathological findings to cancer recurrence and survival.
  
  
  RESULTS
  A total of 510 lymph nodes from 52 patients were examined. The incidence of LNM in pathological complete responders after CRT was 11.5%. Only six patients were found to have AE1/AE3-positive cells in the IHC staining. However, patients with LNM had a higher recurrence rate (50% vs. 22%, P = 0.16) and a reduced disease-free survival rate (44% vs. 75%, P = 0.16). Patients with LNM had a 3.6-fold higher probability to develop recurrence compared with those without LNM (P = 0.15).
  
  
  CONCLUSIONS
  LNMs are uncommon in pathological complete responders but hold prognostic significance.
authors: Graduate Institute of Clinical Medical Sciences, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
authors: Yin-Kai
authors: YK
authors: Chao
authors: Chi-Ju
authors: CJ
authors: Yeh
authors: Wen-Yu
authors: WY
authors: Chuang
authors: Kang-Hsing
authors: KH
authors: Fan
authors: Ming-Ju
authors: MJ
authors: Hsieh
authors: Yen
authors: Y
authors: Chu
authors: Ann-Joy
authors: AJ
authors: Cheng
authors: Hui-Ping
authors: HP
authors: Liu
mesh_terms: D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011379:Prognosis; D018714:Radiotherapy, Adjuvant